RU2426542C2 - Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении - Google Patents

Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении Download PDF

Info

Publication number
RU2426542C2
RU2426542C2 RU2008151713/15A RU2008151713A RU2426542C2 RU 2426542 C2 RU2426542 C2 RU 2426542C2 RU 2008151713/15 A RU2008151713/15 A RU 2008151713/15A RU 2008151713 A RU2008151713 A RU 2008151713A RU 2426542 C2 RU2426542 C2 RU 2426542C2
Authority
RU
Russia
Prior art keywords
amino
dione
pharmaceutically acceptable
acceptable salt
effective amount
Prior art date
Application number
RU2008151713/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2008151713A (ru
Inventor
Доминик ВЕРЕЛЛЬ (US)
Доминик ВЕРЕЛЛЬ
Кайл ЧАНЬ (US)
Кайл ЧАНЬ
Лора КОРРАЛ (US)
Лора КОРРАЛ
ДЕ ПАРСЕВАЛЬ Лор МУТУ (US)
ДЕ ПАРСЕВАЛЬ Лор МУТУ
Хелен БРЭДИ (US)
Хелен БРЭДИ
Original Assignee
Селджин Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селджин Корпорейшн filed Critical Селджин Корпорейшн
Publication of RU2008151713A publication Critical patent/RU2008151713A/ru
Application granted granted Critical
Publication of RU2426542C2 publication Critical patent/RU2426542C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2008151713/15A 2006-05-26 2007-05-24 Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении RU2426542C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80860206P 2006-05-26 2006-05-26
US60/808,602 2006-05-26

Publications (2)

Publication Number Publication Date
RU2008151713A RU2008151713A (ru) 2010-07-10
RU2426542C2 true RU2426542C2 (ru) 2011-08-20

Family

ID=38606531

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008151713/15A RU2426542C2 (ru) 2006-05-26 2007-05-24 Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении

Country Status (11)

Country Link
EP (1) EP2023912A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009538318A (cg-RX-API-DMAC7.html)
KR (1) KR20090014393A (cg-RX-API-DMAC7.html)
CN (1) CN101495111A (cg-RX-API-DMAC7.html)
AU (1) AU2007267928A1 (cg-RX-API-DMAC7.html)
CA (1) CA2652888A1 (cg-RX-API-DMAC7.html)
IL (1) IL195412A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008014912A (cg-RX-API-DMAC7.html)
RU (1) RU2426542C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007139939A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200809956B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101977603A (zh) * 2008-01-29 2011-02-16 细胞基因公司 使用免疫调节化合物来调节cd59水平的方法
WO2013142817A2 (en) * 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
EP3623011B1 (en) * 2013-08-22 2025-02-12 Vanda Pharmaceuticals Inc. Trichostatin a for use in multiple myeloma treatment
JP2016528297A (ja) 2013-08-22 2016-09-15 ヴァンダ ファーマシューティカルズ インコーポレイテッド 癌治療
CN106455542A (zh) * 2014-03-26 2017-02-22 布里格姆及妇女医院股份有限公司 用于人造血干/祖细胞的离体扩增的组合物和方法
WO2015175916A1 (en) * 2014-05-16 2015-11-19 Celgene Corporation Methods and compositions using 4-amino-2-(2,6 dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment of cancers
EP4396331A1 (en) * 2021-09-01 2024-07-10 Flagship Pioneering Innovations VI, LLC Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097052A2 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2004037199A2 (en) * 2002-10-24 2004-05-06 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2005055929A2 (en) * 2003-12-02 2005-06-23 Celgene Corporation Methods and compositions for the treatment and management of hemoglobinopathy and anemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097052A2 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2004037199A2 (en) * 2002-10-24 2004-05-06 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2005055929A2 (en) * 2003-12-02 2005-06-23 Celgene Corporation Methods and compositions for the treatment and management of hemoglobinopathy and anemia

Also Published As

Publication number Publication date
AU2007267928A1 (en) 2007-12-06
WO2007139939A2 (en) 2007-12-06
KR20090014393A (ko) 2009-02-10
CN101495111A (zh) 2009-07-29
ZA200809956B (en) 2010-07-28
JP2009538318A (ja) 2009-11-05
EP2023912A2 (en) 2009-02-18
MX2008014912A (es) 2008-12-10
IL195412A0 (en) 2009-08-03
CA2652888A1 (en) 2007-12-06
WO2007139939A3 (en) 2008-07-03
RU2008151713A (ru) 2010-07-10

Similar Documents

Publication Publication Date Title
US20080051431A1 (en) Methods and compositions using immunomodulatory compounds in combination therapy
AU2004296765B2 (en) Methods and compositions for the treatment and management of hemoglobinopathy and anemia
JP4481828B2 (ja) 骨髄異形成症候群を治療および管理するための免疫調節化合物の使用方法およびそれを含む組成物
US20060154880A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
JP2007534632A (ja) アスベスト関連疾患および障害の治療および管理のための免疫調節化合物の使用方法およびそれを含む組成物
EP1680111A2 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
JP2009538318A (ja) 併用療法において免疫調節化合物を用いる方法及び組成物
WO2005110408A1 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
JP2006510606A (ja) 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物
AU2003286663B2 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
CA2621368A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
HK1133198A (en) Methods and compositions using immunomodulatory compounds in combination therapy
HK1100262B (en) Methods and compositions for the treatment and management of hemoglobinopathy and anemia
HK1111898A (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120525